Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Collegium Pharmaceutical Inc | COLL | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 33.31 | 06:00:13 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 33.31 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 20.83 - 40.95 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 33.31 | USD |
Collegium Pharmaceutical Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.06B | 31.96M | - | 566.77M | 48.16M | 1.51 | 22.11 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Collegium Pharmaceutical News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical COLL Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 32.29 | 33.74 | 30.94 | 32.38 | 570,537 | 1.02 | 3.16% |
| 1 Month | 32.75 | 34.86 | 30.94 | 33.13 | 517,686 | 0.56 | 1.71% |
| 3 Months | 39.37 | 40.95 | 30.42 | 35.27 | 456,308 | -6.06 | -15.39% |
| 6 Months | 27.29 | 40.95 | 27.24 | 34.38 | 460,232 | 6.02 | 22.06% |
| 1 Year | 21.81 | 40.95 | 20.83 | 29.91 | 385,526 | 11.50 | 52.73% |
| 3 Years | 23.22 | 40.95 | 14.04 | 24.32 | 344,407 | 10.09 | 43.45% |
| 5 Years | 11.82 | 40.95 | 10.01 | 22.23 | 372,855 | 21.49 | 181.81% |
Collegium Pharmaceutical Description
| Collegium Pharmaceutical Inc is a specialty pharmaceutical company. It is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release & immediate-release formulations of tapentadol. |
